Fingerprint
Dive into the research topics where Maria Pia Morelli is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach
Pellatt, A. J., Barnett, R. M., Gnerre, S., Edwards, K., Willis, J. A., Overmann, M. J., Raghav, K., Parseghian, C. M., Dasari, A., Morelli, M. P., Bent, A., Eluri, M., Hornstein, N., Drusbosky, L. M., Kopetz, S. & Morris, V. K., Dec 2025, In: BMC cancer. 25, 1, 1201.Research output: Contribution to journal › Article › peer-review
Open Access -
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
Pellatt, A. J., Bent, A., Hornstein, N., Parseghian, C., Huey, R., Raghav, K., Morris, V., Overman, M., Morelli, P., Willis, J., Le, P., Shen, J. P., Kee, B., Eluri, M., Higbie, V., Alfaro-Munoz, K., Aziz, K., Kell, R., Sun, R. & Kopetz, S. & 1 others, , Jul 1 2025, In: JCO Precision Oncology. 9, e2500142.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Scopus citations -
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program
Pellatt, A. J., Maddalena, G., Bent, A. H., Parseghian, C. M., Huey, R. W., Raghav, K. P. S., Morris, V. K., Overman, M. J., Morelli, M. P., Willis, J., Le, P., Shen, J. P. Y. C., Alfaro, K., Aziz, K., Kell, R. J., Sun, R., Kopetz, S. & Dasari, A., 2024, In: Journal of Clinical Oncology. 42, 16, 3623.Research output: Contribution to journal › Article › peer-review
-
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
Smith, C. J., Simeone, D. M., Grierson, P., Kirtane, K., Morelli, M. P., Patel, S. P., Ulrickson, M. L., Dahiya, S., Park, J. C., Specht, J. M., Fakih, M., Liechty, K. B., Tebbets, J., Welch, J. S., Go, W. Y., Maloney, D. G., Maus, M. V., Ng, E. W. C. & Hecht, J. R., Jun 2024, In: Journal of Clinical Oncology. 42, p. 1604 1 p.Research output: Contribution to journal › Review article › peer-review
1 Link opens in a new tab Scopus citations -
INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
Maddalena, G., Pellatt, A. J., Eluri, M., Parseghian, C. M., Aziz, K., Alfaro, K., Kell, R. J., Bent, A. H., Huey, R. W., Uppal, A., Konishi, T., Overman, M. J., Morelli, M. P., Willis, J., Shen, J. P. Y. C., Raghav, K. P. S., Newhook, T. E., Morris, V. K., Dasari, A. & Kopetz, S., 2024, In: Journal of Clinical Oncology. 42, 3_suppl, p. 27 1 p.Research output: Contribution to journal › Article › peer-review
7 Link opens in a new tab Scopus citations